Articles On Starpharma Holdings (ASX:SPL)

Starpharma (ASX:SPL) has announced the presentation of data that it says demonstrate the benefits of combining its DEP irinotecan with other important classes of anti-cancer therapies, including immuno-oncology (IO) agents, in model...

Dimerix’s drug granted QYTOVRA as brand name by US FDA Starpharma completes recruitment for VIRALEZE study in UK Invion adds South Korea to list of exclusive territories for Photosoft    FDA says QYTOVRA can be used as DMX-200 brand name...

  Dr Jackie Fairley – CEO – Starpharma Holdings (ASX:SPL) is a world leader in the development of dendrimer products for pharmaceutical, life science and other applications.

After a stronger-than-expected US inflation figure for August, the Australian August job report blew expectations out of the water, with 64,900 jobs created in the month, well above the 23,000 anticipated by economists. The unemployment rat...

A tech slide dragged the ASX indices lower on Wednesday, ahead of the US inflation data coming in overnight. Consensus expectations were for the US headline consumer price index (CPI) to show core inflation at 3.6% for the year to August, u...

Australian company Starpharma (ASX:SPL) has announced it will present positive interim data from the trial of its DEP irinotecan at a key international oncology conference in October in the US.

ASX 200 falls sharply from the open, tracking Wall St sell off ahead of US CPI read tonight Most sectors decline led by Tech and Industrials Tempus Resources jumps 50%, cops a speeding ticket   Australian shares stepped off the into th...

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, who made announcements today.   ICYMI Leader...

It has been a disappointing day for the S&P/ASX 200 Index (ASX: XJO). In afternoon trade, the benchmark index is down 0.8% to 7,147 points. Four ASX shares that are not letting that hold them back are listed below. Here's why they are...

Starpharm jumps after disclosing interim Phase 1/2 results Chimeric Therapeutics to commence Phase 1b clinical trial Island Pharma gets key patent grant in the US   Starpharma jumps after positive Phase 1/2 results Starpharma (ASX:SPL) ju...

The Starpharma Holdings Ltd (ASX: SPL) share price came rocketing out of the gates this morning. At one stage, the dendrimer products developer's shares were up as much as 58% to 20.5 cents. Starpharma's shares have pulled back a touch sin...

Stockhead’s Top 10 at shortly-before-11-ish, published surprisingly close to on time, considering I was still shaking the tiles off the roof with my snoring when the market doors opened today. It highlights the best (and sometimes worst) pe...

The S&P ASX 200 was down 0.73% in August with mid caps and small caps down 1.3% for the month Eight of 11 sectors down in August with consumer discretionary leading winners and utilities the laggards Tech stock 4DS Memory rises more th...

These four ASX healthcare shares are bucking the trend today with strong share price gains following the release of their latest financial reports. As earnings season continues, the S&P/ASX 200 Health Care Index (ASX: XHJ) is down 0.0...

Local shares to open lower on Monday as US Big Tech retreated Bill Gross says Treasuries are overvalued City Index provides three most common type of scams   The ASX is set to open lower by -0.35% on Monday as Wall Street ended mixed in a...

The ASX couldn’t make up its mind, a bit like economists looking ahead to the RBA decision tomorrow. Health Care and Industrials Stocks had a day to savour, while Staples and IT largely did not. Some standout small caps: TALi Digital, Ecof...

The S&P/ASX 200 Index (ASX: XJO) has started the week in a subdued fashion. In afternoon trade, the benchmark index is down 0.2% to 7,388.3 points. Four ASX shares that are falling more than most today are listed below. Here’s why...

The Starpharma Holdings Ltd (ASX: SPL) share price is ending the month in disastrous fashion. In morning trade, the ASX All Ords biotechnology share is down 34% to a 52-week low of 21.5 cents. Why is this ASX All Ords share being sold off?...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) looks set to end its losing streak. At the time of writing, the benchmark index is up 0.5% to 7,116 points. Four ASX shares that have failed to follow the market higher today are li...

Starpharma (ASX:SPL) has announced the recent presentation of AZD0466 clinical data by AstraZeneca at the European Hematology Association 2023 Hybrid Congress.

The infectious diseases space is one area that could be interesting for ethical investors An ASX company that already has a product in the market is Starpharma Stockhead reached out to Starpharma CEO, Jackie Fairley   Throughout history,...

Anteris’ study is progressing well at the one year and 30-day time points Imugene’s Phase 1 trial has progressed to the next cohort level Nyrada has a new lead drug   Regenerative medicine biotech Anteris Technologies (ASX:AVR) has just p...

Starpharma’s (ASX:SPL) Chief Executive Officer, Dr Jackie Fairely, resigns after 16 years in the role During her tenure, Dr Fairley “transformed” Starpharma from a startup to a “mature organisation” with multiple commercial partnership...

Starpharma (ASX:SPL) has announced that it has achieved regulatory approval for its antiviral nasal spray product, Viraleze, in Malaysia.

OncoSil gets Ethics committee approval Starpharma’s  nasal spray VIRALEZE granted approval in Malaysia Botanix Pharmaceuticals strikes deal in Korea   Medical device OncoSil Medical (ASX:OSL) rose 8% this morning after the Ethics committe...

Biotech Starpharma has received regulatory approval for its Viraleze product to be used in Malaysia, adding the product to a wider market base that now spans 35 countries as it looks into further COVID-19 studies in the UK. The post Starpha...

Starpharma (SPL) secures regulatory approval for its VIRALEZE antiviral nasal spray in Malaysia The registration of VIRALEZE in Malaysia will allow Starpharma and its commercial partners to market and sell the product throughout the coun...

Starpharma (ASX:SPL) has announced the appointment of Justin Cahill as its chief financial officer and company secretary.

What a solid day it’s been for the ASX today, with the benchmark maintaining a strong run past +1.1% for the afternoon, to finish at +1.18% when the bell finally rang, and the old ladies running the ASX called “pencils down” and everyone go...

The S&P/ASX 200 Index (ASX: XJO) has followed Wall Street’s lead and is on course to end the week in the red. At the time of writing, the benchmark index is down 0.8% to 7,094.3 points. Four ASX shares that have not let that hold th...

Biopharmaceutical company Starpharma (SPL) receives a $7.1 million research and development tax incentive refund The tax offset relates to SPL’s Australian and global expenses over the 2022 financial year Starpharma CEO Jackie Fairley...

After yesterday’s pre-Chrimbo spend-up, SPI Futures are down 66 points (-0.38%) this morning, threatening to wipe out yesterday’s 41-point gain. That’s on the back of some good/bad, depends-on-your-worldview news out of the US that data con...

The preliminary results of the clinical trial involving AstraZeneca's AZD0466 and the drug delivery platform developed by Starpharma (ASX:SPL) have been presented at the 2022 American Society of Hematology annual meeting.

Highlights The ASX 200 benchmark index closed in the green today (December 14), gaining 48.00 points, or 0.67%, to end at 7,251.30 points. Over the last five days, the index has gained 0.30%, but is down 2.60% for the last year to date...

Starpharma (SPL) registers its nasal spray product VIRALEZE in Indonesia after gaining marketing authorisationThe company says Indonesia represents an “exciting market opportunity” as its the largest and most populated country in Southeast...

Clarity Pharma announced positive results from Phase 1 trial Starpharma brings VIRALEZE to Indonesia Race Oncology has a new CEO   Clarity Pharma (ASX:CU6) announced that its diagnostic 64Cu SAR-bisPSMA Phase I trial PROPELLER has met all...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a small gain. At the time of writing, the benchmark index is up 0.2% to 7,196.9 points. Four ASX shares that are climbing more than most today are listed belo...

There’s been plenty of insider buying going on among ASX shares lately, and many of the targets are trading at, or around, 52-week lows. That suggests those in the know believe their company is trading at attractive prices. So much so, t...

Starpharma (SPL) spent the September quarter progressing its DEP technology and signing a new research agreementIn mid-August, the company signed a new DEP research agreement with MSD to design and synthesise a number of DEP dendrimer conju...

Starpharma (SPL) signs an agreement with Hengan Pharmacare for the sale and distribution of its nasal spray product, VIRALEZE, in Hong Kong and MacauThe agreement will last for an initial two years and will see Starpharma supply VIRALEZE to...

Blood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks are in the blood clot space Top performing ASX healthcare stocks in the past month Blood clots were top of biotech news this week after re...

The ASX 200 is vacillating Small caps are down over 1.3% Demetallica is a great name and it’s up 40% on takeover talk   The benchmark ASX 200 is flat as on Monday. The ASX Emerging Companies (XEC) index has lost 1.3%. REITs and Gold are h...

Starpharma (SPL) presents promising anti-tumour activity data in prostate cancer at the European Society of Medical Oncology (ESMO) Congress in ParisThe data shows DEP cabazitaxel has a number of key advantages which included superior effic...

Starpharma (ASX:SPL) has been announced as the winner of the ‘Most Significant Commercial Outcome’ award following the completion of a Biomedical Translation Bridge program backed by the federal government’s Medical Research Future...

Starpharma (SPL) signs a new DEP research agreement with MSD, the trade name of Merck Sharp & Dohme Under this agreement, Starpharma will design and synthesise a number of DEP dendrimer conjugates for MSD to test and characterise This...

Starpharma (ASX:SPL) has announced a new research agreement with MSD under which the Australian company will design and synthesise a number of DEP dendrimer conjugates and provide them to the US-based company for testing and charact...

Starpharma (SPL) confirms its VIRALEZE antiviral nasal spray demonstrates a high level of protection against the infectious SARS-CoV-2 Omicron variant In the study, all the test animals were treated with VIRALEZE in vivo in a humanised mou...

After a brutal start to this Friday’s trading session, the All Ordinaries Index (ASX: XAO) has recovered somewhat. At the time of writing, the All Ords is still down by 0.72% at around 6,800 points after going as low as 6,733 points this m...

Starpharma (SPL) relaunches its VIRALEZE nasal spray with LloydsPharmacy in the United Kingdom VIRALEZE will be supplied exclusively to LloydsPharmacy under its existing sales and distribution agreements LloydsPharmacy is one of the larges...

Cann Group’s Mildura facility has been granted GMP licence Paradigm receives patent application acceptance by IP Australia Starpharma to relaunch VIRALZEE with LloydsPharmacy in the UK Cannabis company Cann Group (ASX:CAN) rose 17% this m...